Skip to main content
Premium Trial:

Request an Annual Quote

Germany s MWG Biotech Warns of Year-End Loss; CEO Resigns

NEW YORK, Aug. 27 – Shares in German firm MWG Biotech slid 28 percent on Friday after its chief executive announced his resignation in light of an impending core operating loss for the year.

CEO Michael Weichselgartner, who founded the biotechnology equipment manufacturer, will be replaced on Sept. 1 by Matthias Schönermark, a consultant for MWG from the Boston Consulting Group, the company said.

Schönermark blamed weak market conditions and consultancy costs for the loss, which he said will reach $4.5 million euros, or roughly  $4.1 million. He does not expect MWG to crawl out of the red before 2002.

"Under new management, MWG Biotech now enters the decisive phase of the restructuring process," the company said on its website. "The next months will be dedicated to strategic reorganization with a focused product portfolio, defined structures for turnover and...a strong increase of sales and marketing efforts."

Shares in MWG closed at 2.15 euros on the Neuer Markt on Friday, down from their peak of 30 euros one year ago.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more